June 7, 2013

Anurag Maheshwari, MD, on telaprevir-based HCV treatment

Provided by Healio

June 7, 2013

ORLANDO, Fla. — Anurag Maheshwari, MD, transplant hepatologist at the Institute for Digestive Health and Liver Disease at Mercy Medical Center in Baltimore, discusses his poster, “Sa1059: The Experience with Telaprevir-Based HCV Therapy in Community Practice Does Not Mirror the Clinical Trials Data,” at Digestive Disease Week 2013.

Maheshwari notes that the morbidity associated with telaprevir-based treatment is much greater in real-world practice than had been indicated previously. He urges caution among clinicians in the administration of telaprevir, and stresses the need for rigorous side-effect management protocol and adequate long-term follow-up for patients with HCV receiving this treatment.


No comments:

Post a Comment